• MDA-MB-436人乳腺腺癌细胞(STR鉴定正确)

    价 格:¥1800

    期 货🧑🏽‍🎤:现货(冻存管发2支)

    保藏中心:BTCC

    资源编号:BTCC-1101

    产地🏂🏼:中国

    套 餐𓀌🤵🏻:

    T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

    详细资料说明书下载质检报告(COA)

    Cell line nameMDA-MB-436
    SynonymsMDA_MB_436; MDA MB 436; MDA-Mb-436; MDA-MB436; MDAMB436; MDA-436; MDA436; MB436; MD Anderson-Metastatic Breast-436
    AccessionBTCC-1101
    Resource Identification InitiativeTo cite this cell line use: MDA-MB-436 (BTCC-1101)
    CommentsGroup: Triple negative breast cancer (TNBC) cell line.
    Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
    Part of: COSMIC cell lines project.
    Part of: GrayJW breast cancer cell line panel.
    Part of: ICBP43 breast cancer cell line panel.
    Part of: KuDOS 95 cell line panel.
    Part of: MD Anderson Cell Lines Project.
    Population: Caucasian.
    Doubling time: 89.31 hours (GrayJW panel).
    Microsatellite instability: Instable (MSI-low) (Sanger).
    Omics: Array-based CGH.
    Omics: Chromatin accessibility by ATAC-seq.
    Omics: CNV analysis.
    Omics: Deep exome analysis.
    Omics: Deep quantitative proteome analysis.
    Omics: DNA methylation analysis.
    Omics: Glycoproteome analysis by proteomics.
    Omics: H2BK120ub ChIP-seq epigenome analysis.
    Omics: H3K4me3 ChIP-seq epigenome analysis.
    Omics: H3K23ac ChIP-seq epigenome analysis.
    Omics: H3K27ac ChIP-seq epigenome analysis.
    Omics: H3K27me3 ChIP-seq epigenome analysis.
    Omics: H3K36me3 ChIP-seq epigenome analysis.
    Omics: H3K4me1 ChIP-seq epigenome analysis.
    Omics: H3K4me3 ChIP-seq epigenome analysis.
    Omics: H3K79me2 ChIP-seq epigenome analysis.
    Omics: H3K9ac ChIP-seq epigenome analysis.
    Omics: H3K9me3 ChIP-seq epigenome analysis.
    Omics: H4K8ac ChIP-seq epigenome analysis.
    Omics: miRNA expression profiling.
    Omics: Protein expression by reverse-phase protein arrays.
    Omics: SNP array analysis.
    Omics: Transcriptome analysis by microarray.
    Omics: Transcriptome analysis by RNAseq.
    Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
    Sequence variations
    • Gene deletion; HGNC; 3701; FHIT; Zygosity=Homozygous (PubMed=9288768).
    • Mutation; HGNC; 1100; BRCA1; Simple; c.5277+1G>A; ClinVar=VCV000037654; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=16397213; PubMed=19593635).
    • Mutation; HGNC; 9884; RB1; Simple; p.Gly203fs*9 (c.607_608ins227); Zygosity=Homozygous (PubMed=19593635).
    • Mutation; HGNC; 11998; TP53; Simple; p.Glu204fs*7 (c.610_612delinsGCGTGTGG); Zygosity=Unspecified (PubMed=16541312; PubMed=28889351).
    HLA typingSource: PubMed=26589293
    Class I
    HLA-AA*01:01,01:01
    HLA-BB*08:01,08:01
    HLA-CC*07:01,07:01
    Class II
    HLA-DQDQA1*02:01,05:02

    DQB1*04:01,04:01
    HLA-DRDRB1*03:01,11:30
    Genome ancestrySource: PubMed=30894373

    Origin% genome


    African1.41
    Native American0
    East Asian, North2.21
    East Asian, South0
    South Asian0
    European, North63.9
    European, South32.49
    DiseaseInvasive breast carcinoma of no special type (NCIt: C4194)
    Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
    HierarchyChildren:


    CVCL_JY98 (MDA-MB-436/GFP)CVCL_JY99 (MDA-MB-436/RFP)
    Sex of cellFemale
    Age at sampling43Y
    CategoryCancer cell line
    STR profileSource(s): ATCC; CCRID; CLS; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=25877200; PubMed=28889351

    Markers:
    AmelogeninX
    CSF1PO12
    D1S165617.3,19.3
    D2S44110
    D2S133823
    D3S135818
    D5S81813
    D7S82010
    D8S117910,14
    D10S124813,14
    D12S39120
    D13S31710
    D16S5399 (CLS; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=25877200)
    9,11 (ATCC; CCRID; PubMed=28889351)
    D18S5112
    D19S43313
    D21S1130,31.2
    D22S104517
    FGA21,24 (CCRID)
    24 (CLS; Genomics_Center_BCF_Technion; PubMed=25877200)
    Penta D9
    Penta E10,12
    TH019.3
    TPOX8
    vWA14,20

    Run an STR similarity search on this cell line
    Web pageshttps://lincs.hms.harvard.edu/resources/reagents/icbp43/
    http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-436
    https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
    https://tcpaportal.org/mclp/
    Publications

    PubMed=730202; DOI=10.1007/BF02616120
    Cailleau R.M., Olive M., Cruciger Q.V.J.
    Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
    In Vitro 14:911-915(1978)

    PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1
    Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.
    Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.
    Cancer Genet. Cytogenet. 3:61-73(1981)

    PubMed=3518877; DOI=10.3109/07357908609038260
    Fogh J.
    Human tumor lines for cancer research.
    Cancer Invest. 4:157-184(1986)

    PubMed=1961733; DOI=10.1073/pnas.88.23.10657
    Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.
    Mutations in p53 as potential molecular markers for human breast cancer.
    Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)

    DOI=10.1016/B978-0-12-333530-2.50009-5
    Leibovitz A.
    Cell lines from human breast.
    (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994)

    PubMed=9288768
    Ahmadian M., Wistuba I.I., Fong K.M., Behrens C., Kodagoda D.R., Saboorian M.H., Shay J., Tomlinson G.E., Blum J., Minna J.D., Gazdar A.F.
    Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
    Cancer Res. 57:3664-3668(1997)

    PubMed=9823299
    Khan J., Simon R.M., Bittner M., Chen Y., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.
    Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
    Cancer Res. 58:5009-5013(1998)

    PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::aid-gcc9>3.0.CO;2-B
    Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J., Larsson C.
    Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
    Genes Chromosomes Cancer 28:308-317(2000)

    PubMed=10969801
    Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
    Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
    Cancer Res. 60:4519-4525(2000)

    PubMed=15677628; DOI=10.1093/carcin/bgi032
    Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
    Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
    Carcinogenesis 26:923-930(2005)

    PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
    Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
    BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
    Cancer Res. 66:41-45(2006)

    PubMed=16541312; DOI=10.1007/s10549-006-9186-z
    Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
    Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
    Breast Cancer Res. Treat. 99:97-101(2006)

    PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
    Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
    A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
    Cancer Cell 10:515-527(2006)

    PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004
    Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.
    The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
    Mol. Oncol. 1:84-96(2007)

    PubMed=19582160; DOI=10.1371/journal.pone.0006146
    Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
    Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    PLoS ONE 4:E6146-E6146(2009)

    CLPUB00423
    Morrison B.J.
    Breast cancer stem cells: tumourspheres and implications for therapy.
    Thesis PhD (2010), Griffith University, Australia

    PubMed=19593635; DOI=10.1007/s10549-009-0460-8
    Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
    Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
    Breast Cancer Res. Treat. 121:53-64(2010)

    PubMed=21778573; DOI=10.3233/BD-2010-0307
    Chavez K.J., Garimella S.V., Lipkowitz S.
    Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
    Breast Dis. 32:35-48(2010)

    PubMed=22460905; DOI=10.1038/nature11003
    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Nature 483:603-607(2012)

    PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
    Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
    Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
    Cancer Discov. 2:172-189(2012)

    PubMed=23151021; DOI=10.1186/1471-2164-13-619
    Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
    Molecular characterisation of cell line models for triple-negative breast cancers.
    BMC Genomics 13:619.1-619.14(2012)

    PubMed=23601657; DOI=10.1186/bcr3415
    Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
    miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
    Breast Cancer Res. 15:R33.1-R33.17(2013)

    PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
    Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
    Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
    Cancer Cell 24:450-465(2013)

    PubMed=24162158; DOI=10.1007/s10549-013-2743-3
    Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
    Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
    Breast Cancer Res. Treat. 142:237-255(2013)

    PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
    Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
    Modeling precision treatment of breast cancer.
    Genome Biol. 14:R110.1-R110.14(2013)

    PubMed=25485619; DOI=10.1038/nbt.3080
    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
    A comprehensive transcriptional portrait of human cancer cell lines.
    Nat. Biotechnol. 33:306-312(2015)

    PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050
    Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.
    The proteomic landscape of triple-negative breast cancer.
    Cell Rep. 11:630-644(2015)

    PubMed=26589293; DOI=10.1186/s13073-015-0240-5
    Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
    TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
    Genome Med. 7:118.1-118.7(2015)

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
    A landscape of pharmacogenomic interactions in cancer.
    Cell 166:740-754(2016)

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
    Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
    Characterization of human cancer cell lines by reverse-phase protein arrays.
    Cancer Cell 31:225-239(2017)

    PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470
    Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
    Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
    J. Proteome Res. 16:1391-1400(2017)

    PubMed=28889351; DOI=10.1007/s10549-017-4496-x
    Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res. Treat. 167:289-301(2018)

    PubMed=29273624; DOI=10.1101/gr.226019.117
    Franco H.L., Nagari A., Malladi V.S., Li W.-Q., Xi Y.-X., Richardson D., Allton K.L., Tanaka K., Li J., Murakami S., Keyomarsi K., Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.
    Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
    Genome Res. 28:159-170(2018)

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
    Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
    Cancer Res. 79:1263-1273(2019)

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3
    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
    Next-generation characterization of the Cancer Cell Line Encyclopedia.
    Nature 569:503-508(2019)

    PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
    Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
    Quantitative proteomics of the Cancer Cell Line Encyclopedia.
    Cell 180:387-402.e16(2020)

    PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
    Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
    Pan-cancer proteomic map of 949 human cell lines.
    Cancer Cell 40:835-849.e8(2022)

    Cross-references
    Cell line databases/resourcesCLO; CLO_0007639
    CLDB; cl7218
    CCRID; 1101HUM-PUMC000352
    CCRID; 3101HUMTCHu184
    Cell_Model_Passport; SIDM00629
    Cosmic-CLP; 1240172
    DepMap; ACH-000573
    LINCS_HMS; 50333
    LINCS_LDP; LCL-1470
    SLKBase; 3609
    TOKU-E; 2399
    Anatomy/cell type resourcesBTO; BTO:0001568
    Biological sample resourcesBioSample; SAMN03471588
    BioSample; SAMN03472712
    BioSample; SAMN10987901
    Cell line collections (Providers)ATCC; HTB-130
    CLS; 300278 - Discontinued
    ICLC; HTL11005
    IZSLER; BS TCL 246
    Chemistry resourcesChEMBL-Cells; CHEMBL4295382
    ChEMBL-Targets; CHEMBL4296465
    GDSC; 1240172
    PharmacoDB; MDAMB436_905_2019
    PubChem_Cell_line; CVCL_0623
    Encyclopedic resourcesWikidata; Q54904639
    Experimental variables resourcesEFO; EFO_0001214

    更多>>相关产品

    总部地址👷‍♀️:北京市怀柔区渤海镇怀沙路536号

    关注杏鑫
    在线咨询
    在线客服
    电话咨询
    微信客服
    返回顶部
    杏鑫娱乐专业提供:杏鑫娱乐🧏🏽‍♀️、杏鑫💇‍♂️、杏鑫平台等服务,提供最新官网平台、地址、注册、登陆、登录、入口、全站、网站、网页、网址、娱乐、手机版、app、下载、欧洲杯、欧冠、nba、世界杯、英超等,界面美观优质完美,安全稳定,服务一流,杏鑫娱乐欢迎您。